What indication should be documented for olanzapine (Zyprexa) use in a 73-year-old patient receiving hospice care who is taking 2.5 mg daily?

Appropriate Indication for Olanzapine 2.5 mg Daily in a 73-Year-Old Hospice Patient

For a 73-year-old hospice patient on olanzapine 2.5 mg daily, document the indication as "management of refractory nausea/vomiting" or "delirium with agitation" or "cancer-related anorexia" - whichever symptom is most prominent in this patient's clinical presentation.

Clinical Context and Rationale

The 2.5 mg daily dose is appropriate for elderly hospice patients and aligns with guideline-recommended starting doses for this population. ESMO guidelines specifically recommend olanzapine 2.5-5 mg daily for older patients, with the lower end of this range preferred in elderly or frail individuals 1. The FDA label confirms that elderly patients have approximately 1.5 times longer elimination half-life, necessitating dose reduction 2.

Most Likely Indications in Hospice Care

Primary Indications (Choose Based on Patient's Symptoms):

1. Refractory Nausea and Vomiting

• Most common off-label use in palliative care
• Evidence shows 82% improvement in anorexia symptoms and 50% relief of refractory nausea at 2.5 mg daily 3
• Nausea scores decreased from 6.1 to 1.8 with ≤5 mg daily dosing 4
• Particularly effective for multifactorial nausea (opioid-induced, disease-related, or chemotherapy-related)

2. Delirium Management

• ESMO guidelines explicitly list olanzapine as a neuroleptic for managing delirium in end-of-life care 5
• Recommended starting dose: 2.5-5 mg daily, with lower doses for elderly patients 1
• Particularly indicated when patient has perceptual disturbances (hallucinations, illusions) or agitation
• Critical caveat: Distinguish delirium from anxiety, as benzodiazepines can worsen delirium 5

3. Cancer-Related Anorexia

• 82% of patients maintained or gained weight on 2.5 mg daily 3
• Addresses cancer anorexia-cachexia syndrome
• May provide additional benefit for associated anxiety and insomnia

Documentation Recommendations

Write the indication as one of the following (select the most clinically relevant):

• "Refractory nausea and vomiting in advanced cancer"
• "Terminal delirium with agitation"
• "Cancer-related anorexia-cachexia syndrome"
• "Palliative symptom management (specify: nausea/delirium/anorexia)"

Important Clinical Considerations

Safety Profile in Elderly Hospice Patients:

• The 2.5 mg dose is conservative and appropriate for this age group
• Most common adverse effect is somnolence (18% incidence) 4
• Risk of orthostatic hypotension and falls - monitor accordingly 1
• Avoid combining with benzodiazepines due to risk of oversedation and respiratory depression 1

Monitoring Parameters:

• Assess for paradoxical agitation (can occur with antipsychotics)
• Watch for extrapyramidal symptoms, though less common with olanzapine
• Monitor for excessive sedation, particularly if combined with opioids

Duration of Therapy:

• In hospice care, continue as long as symptom benefit persists
• ESMO guidelines state medications for symptom palliation should be continued unless ineffective or causing distressing side effects 5
• For patients with longer prognosis, consider periodic reassessment of need 6

Common Pitfalls to Avoid

1. Don't document vague indications like "comfort care" - be specific about the target symptom
2. Don't assume it's for psychiatric disease unless the patient has a documented psychiatric history requiring antipsychotic therapy
3. Don't overlook delirium - this is easily confused with anxiety but requires different management
4. Don't combine with benzodiazepines without careful consideration of respiratory depression risk 1

The specific indication you document should reflect the actual symptom being treated. Review the patient's chart for recent symptom assessments to determine whether nausea, delirium, anorexia, or another palliative symptom is the primary target.